PLASMA KALLIKREIN INHIBITORS

The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angio...

Full description

Saved in:
Bibliographic Details
Main Authors TIAN, Maoqun, MANDAL, Mihir, LOPEZ, Jovan Alexander, YANG, Song, GAO, Ying-Duo, HE, Jiafang, CHENG, Alan
Format Patent
LanguageEnglish
French
Published 27.10.2022
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein. La présente invention concerne un composé de formule I et des compositions pharmaceutiques comprenant un ou plusieurs desdits composés, et des méthodes d'utilisation desdits composés pour traiter ou prévenir un ou plusieurs états pathologiques qui pourraient bénéficier de l'inhibition de la kallikréine plasmatique, notamment l'angiœdème héréditaire, l'uvéite, l'uvéite postérieure, la dégénérescence maculaire liée à l'âge humide, l'œdème maculaire diabétique, la rétinopathie diabétique et l'occlusion veineuse rétinienne. Les composés sont des inhibiteurs sélectifs de la kallikréine plasmatique.
Bibliography:Application Number: WO2022US25159